SCHEMBL300513

SCHEMBL300513

O=C(O)c1n[nH]c2c1CCCCC2=Cc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
HTT P42858 2/20 0.46
HCAR2 Q8TDS4 2/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C1 Q04828 1/20 0.43
MAPT P10636 3/20 0.39
HPGD P15428 1/20 0.39
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
EGFR P00533 1/20 0.36
CNR1 P21554 2/20 0.36
CNR2 P34972 1/20 0.36
CDK1 P06493 1/20 0.36
CDK2 P24941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915235 1.00 NPC1 (0.46) NPC1HTTHCAR2KMT2ATSHR
SCHEMBL14258958 0.89 NPC1 (0.47) NPC1HTTAKR1C3AKR1C1ALDH1A1
SCHEMBL4912008 0.86 CYP1A2 (0.50) NPC1HTTHCAR2KMT2ATSHR
SCHEMBL4223942 0.86 CYP1A2 (0.50) NPC1HTTHCAR2KMT2ATSHR
SCHEMBL176863 0.84 NPC1 (0.43) NPC1HTTKMT2AAKR1C3AKR1C1
SCHEMBL176864 0.84 NPC1 (0.43) NPC1HTTKMT2AAKR1C3AKR1C1
SCHEMBL176623 0.81 NPC1 (0.46) NPC1HTTCNR1CNR2
SCHEMBL176622 0.81 NPC1 (0.46) NPC1HTTCNR1CNR2
SCHEMBL176483 0.80 CNR1 (0.56) NPC1HTTALDH1A1LMNACNR1
SCHEMBL176790 0.80 CNR1 (0.56) NPC1HTTALDH1A1LMNACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378096-B2 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US claimed
EP-1937259-B1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-11-23 EP claimed
US-20080234347-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-25 US claimed
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-20 US claimed
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 US claimed
US-8378096-B2 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US disclosed
US-20090197886-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-08-06 US disclosed
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197886-A1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS CNR2, CNR1, FAAH NPC1 601/4885HTT 440/4885HCAR2 11/4885
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators CNR2, CNR1, FAAH NPC1 601/4885HTT 440/4885HCAR2 11/4885
US-20080234347-A1 METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN CNR2, CNR1, NPY4R NPC1 1286/4885HTT 4180/4885HCAR2 66/4885
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators CNR2, CNR1, FAAH NPC1 601/4885HTT 440/4885HCAR2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.